Shionogi & Co., Ltd. (FRA:SH0)
Germany · Delayed Price · Currency is EUR | Market Cap | 14.71B +24.4% |
| Revenue (ttm) | 3.03B +27.9% |
| Net Income | 1.42B +47.1% |
| EPS | 1.76 +47.0% |
| Shares Out | n/a |
| PE Ratio | 9.28 |
| Forward PE | n/a |
| Dividend | 0.42 (2.56%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | n/a |
| Open | 16.35 |
| Previous Close | 16.25 |
| Day's Range | 16.35 - 16.35 |
| 52-Week Range | 13.10 - 19.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Shionogi &
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothol... [Read more]
Financial Performance
In fiscal year 2026, Shionogi &'s revenue was 499.68 billion, an increase of 14.01% compared to the previous year's 438.27 billion. Earnings were 205.16 billion, an increase of 20.37%.
Financial numbers in JPY Financial StatementsNews
IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) will present new data at IDWeek 2026 that reinforc...
Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meetin...
Shionogi to Acquire IntraBio for $2 Billion
The Japanese drugmaker said IntraBio's expertise would strengthen capabilities across its rare disease pipeline.
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present fin...
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research an...
Shionogi & Quarterly report: Q1 2027
Shionogi & has published its Q1 2027 quarterly earnings report on August 3, 2026.
Shionogi & Slides: Q1 2027
Shionogi & has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 3, 2026.
Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter, “Shionogi”) today announced the four-year anniversary o...
FDA Accepts Shionogi's sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shiono...
Shionogi & Slides: Investor presentation
Shionogi & has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
OSAKA, Japan--(BUSINESS WIRE)--Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure.
US regulator approves oral drug from Japan's Shionogi to prevent COVID-19
Japan's Shionogi & Co said on Monday the U.S. Food and Drug Administration has approved its oral antiviral Ensitrelvir, commercially known as Xocova, for the preventive treatment of individuals wh...
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-bli...
Shionogi & Quarterly report: Q4 2026
Shionogi & has published its Q4 2026 quarterly earnings report on May 12, 2026.
Shionogi & Slides: Q4 2026
Shionogi & has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 12, 2026.
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi Inc., a New Jersey-based s...
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer of a...
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in Espr...
Shionogi & Quarterly report: Q3 2026
Shionogi & has published its Q3 2026 quarterly earnings report on January 29, 2026.
Shionogi & Slides: Q3 2026
Shionogi & has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 29, 2026.
Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits
Japan's Shionogi & Co said on Tuesday it would pay $2.13 billion for new shares in joint venture ViiV Healthcare, increasing its stake in the HIV drugmaker to 21.7% as U.S. drugmaker Pfizer exits its ...
Shionogi & Slides: Sustainability presentation
Shionogi & has posted slides in relation to its latest quarterly earnings report, which was published on December 11, 2025.
Shionogi & Quarterly report: Q2 2026
Shionogi & has published its Q2 2026 quarterly earnings report on October 27, 2025.
Shionogi & Slides: Q2 2026
Shionogi & has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 27, 2025.
Shionogi & Quarterly report: Q1 2026
Shionogi & has published its Q1 2026 quarterly earnings report on July 28, 2025.